SciSparc Begins Patient Recruitment for Autism Clinical Trial
Ticker: SPRC · Form: 6-K · Filed: Jan 29, 2024 · CIK: 1611746
| Field | Detail |
|---|---|
| Company | Scisparc Ltd. (SPRC) |
| Form Type | 6-K |
| Filed Date | Jan 29, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Complexity: simple
Sentiment: bullish
Topics: clinical-trial, drug-development, biotechnology, pharmaceuticals
TL;DR
**SciSparc just started recruiting for its autism drug trial, big step for their pipeline!**
AI Summary
On January 29, 2024, SciSparc Ltd. announced the initiation of patient recruitment for its clinical trial using SCI-210 to treat children with Autism Spectrum Disorder. This is a significant step for the company as it moves its drug candidate closer to potential market approval. For investors, this progress in a clinical trial could signal future growth opportunities and increased stock value if the trial proves successful, as it addresses a critical unmet medical need.
Why It Matters
This filing indicates SciSparc is actively progressing its drug development pipeline, which is crucial for a pharmaceutical company's long-term value and potential for future revenue streams.
Risk Assessment
Risk Level: medium — While progress is positive, clinical trials inherently carry high risk of failure, which could negatively impact the stock.
Analyst Insight
A smart investor would monitor news regarding the SCI-210 clinical trial's progress and any interim results, as successful outcomes could significantly boost SciSparc's valuation.
Key Players & Entities
- SciSparc Ltd. (company) — the registrant and pharmaceutical company
- SCI-210 (other) — the drug candidate being tested
- Autism Spectrum Disorder (other) — the condition being treated in the clinical trial
- January 29, 2024 (date) — date of the press release and report
Forward-Looking Statements
- SciSparc's stock price will see increased volatility as the clinical trial progresses. (SciSparc Ltd.) — medium confidence, target: next 6-12 months
- Positive interim results from the SCI-210 trial could lead to a significant stock price increase. (SciSparc Ltd.) — medium confidence, target: next 1-2 years
FAQ
What is the specific drug candidate SciSparc Ltd. is testing in its new clinical trial?
SciSparc Ltd. is testing SCI-210 in its new clinical trial, as stated in the press release furnished as Exhibit 99.1.
For what condition is SciSparc Ltd. initiating patient recruitment for its clinical trial?
SciSparc Ltd. is initiating patient recruitment for a clinical trial in children with Autism Spectrum Disorder, according to the press release titled 'SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder' issued on January 29, 2024.
When did SciSparc Ltd. issue the press release regarding the initiation of patient recruitment?
SciSparc Ltd. issued the press release on January 29, 2024, as indicated in the filing.
What is the purpose of furnishing the press release as Exhibit 99.1 in this 6-K filing?
The press release is furnished as Exhibit 99.1 to provide details about the initiation of patient recruitment for the clinical trial and is incorporated by reference into the Company's registration statements on Form F-3 and Form S-8.
Into which specific SEC registration statements is the press release from this 6-K filing incorporated by reference?
The press release is incorporated by reference into the Company’s registration statements on Form F-3 (File No. 333-275305, File No. 333-269839, File No. 333-266047, File No. 333-233417, File No. 333-248670, File No. 333-255408, and File No. 333-275305) and on Form S-8 (File No. 333-225773).
Filing Stats: 326 words · 1 min read · ~1 pages · Grade level 8.8 · Accepted 2024-01-29 16:00:11
Filing Documents
- ea192348-6k_scisparc.htm (6-K) — 12KB
- ea192348ex99-1_scisparc.htm (EX-99.1) — 11KB
- 0001213900-24-007379.txt ( ) — 25KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SciSparc Ltd. Date: January 29, 2024 By: /s/ Oz Adler Name: Oz Adler Title: Chief Executive Officer and Chief Financial Officer 3